Oncotarget

Researchers Noriyuki Hirahara, Takeshi Matsubara, and Shunsuke Kaji discuss a new prognostic index for gastric cancer survival outcomes. They highlight the importance of inflammatory responses in cancer growth and the development of ICPI as a predictive marker. The podcast explores the significance of LMR, NLR, and PLR in determining cancer-specific survival and emphasizes the potential impact of preoperative interventions based on ICPI.

Researchers discuss the effects of Everolimus on inhibiting angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma, leading to improved progression-free survival. They delve into the molecular mechanisms of mutant P53 protein activating the mTOR pathway and how Everolimus reduces the STAT3-HIF-1 alpha VEGF pathway in tumor models.

New research perspective explores the potential of CD200 as a cancer therapy target due to its role in promoting an immunosuppressive tumor microenvironment. The CD200 blocking antibody Somalizumab is being tested, but alternative mechanisms beyond T cell suppression may offer new avenues for treatment in human cancers.

Discover the vital role of CD56 in combating multiple myeloma, a complex blood cancer impacting plasma cells in the bone marrow. With new research shedding light on CD56 as a biomarker and therapeutic target, potential treatments aim to improve patient outcomes. Learn about the ongoing studies targeting CD56 for innovative therapies, including drug inhibition and immunotherapies, to address the heterogeneity of multiple myeloma.

Experts in B-cell lymphoma research discuss an updated analysis from a phase I study of mivavotinib for relapsed/refractory B-cell lymphoma, focusing on diffuse large B-cell lymphoma. They delve into the drug's mechanism of action, patient enrollment, treatment protocol, response rates, efficacy on DLBCL responders, median response duration, ORR in subgroups, progression-free survival rates, treatment emergent adverse events, and SYK as a potential therapeutic target for B-cell lymphomas.

Researchers Joshua D. Bernstock, Sarah Blitz, Kyung-Don Kang, and Gregory K. Friedman discuss Intraventricular Immunovirotherapy in cancer treatment using engineered type 1 herpes simplex virus. They highlight its efficacy in recent clinical trials for high-grade glioma and potential for targeting intractable diseases like disseminated medulloblastoma. The importance of Intraventricular Administration for targeted immunovirotherapy is emphasized.

Researchers Jessica T. Gomes and Ana Márcia V. Wanzeler discuss a study comparing Andiroba oil and low-level laser therapy in treating oral mucositis. They explore the healing and toxicological effects of Andiroba oil, highlighting its potential for inflammatory disease treatment.

Researchers discuss the potential of targeting DLST for cancer therapy in neuroblastoma and TNBC, with implications for inducing apoptosis. They identify approved drugs with high effectiveness for DLST+ tumor cell lines, suggesting vulnerability to protein kinase inhibitors and ERK/MAPK pathway targeting drugs.

Researchers explore the potential of STRO-001 in B-cell NHL, showing potent cytotoxicity in cancer cell lines, promising results in preclinical studies for tumor regression and eradication

Researchers discuss the chemotherapeutic potential of 15d-PMJ2 in inducing cell death in melanoma and squamous cell carcinoma cell lines. The involvement of PERK, IP3R, and mitochondrial calcium signaling pathways in this process is highlighted. Experiments reveal the importance of ER stress, calcium release, and mitochondrial permeability transition pore in the mechanism of cell death.